| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Budget impact analysis of a personalized HBeAg negative CHB antiviral therapy model
|
Iannazzo, S.
|
|
2013
|
45 |
S6 |
p. e369-
1 p.
|
article
|
| 2 |
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
|
Petta, S.
|
|
2013
|
45 |
S6 |
p. e371-
1 p.
|
article
|
| 3 |
Identification and consumption of hepatopathic patients in Tuscany Region: Limits and opportunities of administrative data
|
Vainieri, M.
|
|
2013
|
45 |
S6 |
p. e369-e370
nvt p.
|
article
|
| 4 |
Identification of responders to sorafenib in hepatocellular carcinoma: Is tumour volume measurement the way forward?
|
Sacco, R.
|
|
2013
|
45 |
S6 |
p. e370-
1 p.
|
article
|
| 5 |
Normocaloric low cholesterol diet modulates Th17/Treg balance in patients with chronic hepatitis C virus infection
|
Maggio, R.
|
|
2013
|
45 |
S6 |
p. e367-e368
nvt p.
|
article
|
| 6 |
Operational study on HBV/HCV in migrants in the Calabria Region (North Africa Emergency Program): Prevalence, HBsAg chronic carriers and outcomes
|
Surace, L.A.
|
|
2013
|
45 |
S6 |
p. e368-
1 p.
|
article
|
| 7 |
Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
|
Petta, S.
|
|
2013
|
45 |
S6 |
p. e370-
1 p.
|
article
|
| 8 |
Personalized sorafenib therapy for hepatocellular carcinoma
|
Cabibbo, G.
|
|
2013
|
45 |
S6 |
p. e371-
1 p.
|
article
|
| 9 |
Protective effect of the Y220C mutant p53 during steatosis: Good news?
|
Gori, M.
|
|
2013
|
45 |
S6 |
p. e368-e369
nvt p.
|
article
|
| 10 |
P53 status influences copper homeostasis in experimental model of hepatic steatosis
|
Arciello, M.
|
|
2013
|
45 |
S6 |
p. e368-
1 p.
|
article
|
| 11 |
Rs4374383 single nucleotide polymorphism of MERTK gene influences the development of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis
|
Di Marco, V.
|
|
2013
|
45 |
S6 |
p. e367-
1 p.
|
article
|
Journal description